- ALNY +13.12%
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight
Yahoo Finance · 7 hours ago
Open | 250.00 |
High | 271.01 |
Low | 245.17 |
Mkt Cap | 33.98B |
P/E (TTM) | N/A |
Div & Yield | N/A & N/A |
Prev. Close | 237.46 |
52 Wk. Low | 141.98 |
52 Wk. High | 271.01 |
Related stocks
Biopharmaceutical company
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. Wikipedia
(USD) | Q2 2024 | Y/Y |
---|---|---|
Revenue | 659.83M | 107.00% ▲ |
Net Income | -16.89M | - |
Diluted EPS | -0.13 | - |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q3 2024 | -$1.03 | - |
Q2 2024 | -$1.08 | -$0.13 |
Q1 2024 | -$1.18 | -$0.52 |
S&P FuturesES=F | 5,417.50-62.75 (-1.15%) |
Dow FuturesYM=F | 40,200.00-314.00 (-0.78%) |
Nasdaq FuturesNQ=F | 18,683.50-339.75 (-1.79%) |
29.05-5.50% | |
Amazon.com, Inc.AMZN | 184.07-1.56% |
152.62-4.89% |